COLL
COLLEGIUM PHARMACEUTICAL, INCMarquee-fund ownership over time
This quarter's activity
New positions opened
None.
Positions exited
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Renaissance Technologies | Q3 2024(8Q snapshot) | 7Q | $36 | $34 | -5% |
| Citadel Advisors | Q3 2024(8Q snapshot) | 7Q | $34 | $34 | -2% |
| D.E. Shaw | Q3 2024(8Q snapshot) | 7Q | $34 | $34 | -2% |
| AQR Capital Management | Q3 2024(8Q snapshot) | 7Q | $34 | $34 | -2% |
| Millennium Management | Q3 2024(8Q snapshot) | 7Q | $34 | $34 | -2% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Two Sigma Investments 2× in & out | Q1 2026 | Q2 2026 | — | +0% |
| Maverick Capital 6× in & out | Q2 2024 | Q4 2024 | → $30 | -11% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at COLLEGIUM PHARMACEUTICAL, INC. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from May 20, 2026 — the most recent Form 4 on file — not from today.
- Form 40001296771-26-000004May 20, 2026
- Form 40001450485-26-000009May 18, 2026
- Form 40001606244-26-000002May 18, 2026
- Form 40001296771-26-000002May 18, 2026
- Form 40002134015-26-000005May 18, 2026
- Form 40001254705-26-000004May 18, 2026
- Form 40001825625-26-000002May 18, 2026
- Form 40001276038-26-000002May 18, 2026
- Form 40001450485-26-000007May 15, 2026
- Form 40001254705-26-000002May 13, 2026
- Form 40002061438-26-000009Apr 3, 2026
- Form 40002061438-26-000006Mar 20, 2026
- Form 40002061438-26-000004Mar 11, 2026
- Form 40001746251-26-000004Mar 5, 2026
- Form 40002061438-26-000002Feb 12, 2026
Fundamentals
XBRL · COLLEGIUM PHARMACEUTICAL, INCAnnual figures sourced directly from COLLEGIUM PHARMACEUTICAL, INC's 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for COLLEGIUM PHARMACEUTICAL, INC — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KFORM 8-KMay 15, 2026
- 8-KFORM 8-KMay 12, 2026
- 10-QQuarterly reportMay 7, 2026
- 8-KMaterial eventMay 7, 2026
- DEF 14AProxy statementApr 7, 2026
- 8-KMaterial eventApr 7, 2026
- 8-KFORM 8-KMar 19, 2026
- 10-KAnnual reportFeb 26, 2026
- 8-KMaterial eventFeb 26, 2026
- 8-KFORM 8-KJan 8, 2026
- 8-KFORM 8-KDec 30, 2025
- 10-QQuarterly reportNov 6, 2025
- 8-KMaterial eventNov 6, 2025
- 10-QQuarterly reportAug 7, 2025
- 8-KMaterial eventAug 7, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Two Sigma Investments | Q1 2026 | Q2 2026 | $0.00 | — | +0% |
| Citadel Advisors | Q3 2024 | open | $34 | $34 | -2% |
| Two Sigma Investments | Q3 2024 | open | $34 | $34 | -2% |
| D.E. Shaw | Q3 2024 | open | $34 | $34 | -2% |
| AQR Capital Management | Q3 2024 | open | $34 | $34 | -2% |
| Millennium Management | Q3 2024 | open | $34 | $34 | -2% |
| Renaissance Technologies | Q3 2024 | open | $36 | $34 | -5% |
| Maverick Capital | Q2 2024 | Q4 2024 | $34 | $30 | -11% |
| Maverick Capital | Q4 2022 | Q4 2023 | $20 | $25 | +26% |
| Maverick Capital | Q3 2021 | Q4 2021 | $20 | $20 | -2% |
| Maverick Capital | Q1 2021 | Q2 2021 | $25 | $23 | -7% |
| Maverick Capital | Q2 2019 | Q3 2019 | $13 | $11 | -14% |
| Maverick Capital | Q3 2018 | Q1 2019 | $17 | $14 | -20% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.